Oncotelic Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncotelic Therapeutics, Inc.
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
Japanese firm extricates itself from international deals for oral anemia drug, leaving Akebia potentially needing to find a new partner to progress development and commercialization.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
- Large Molecule
- Other Names / Subsidiaries
- Mateon Therapeutics, Inc.
- OXiGENE, Inc.
- PointR Data, Inc.